What does Pharmosa Biopharm Inc. do?

Pharmosa Biopharm Inc. (6875.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6875.TWO's market cap?

Pharmosa Biopharm Inc. (6875.TWO) has a market capitalization of approximately $4.26 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 6875.TWO pay a dividend?

No — Pharmosa Biopharm Inc. (6875.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6875.TWO profitable?

Pharmosa Biopharm Inc. (6875.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6875.TWO

Pharmosa Biopharm Inc.

TWO·Biotechnology · Healthcare

NT$33.00NT$1.00+3.13%

Market capNT$4.26B·Market closed·Aug 26 5:30 AM UTC

Price Chart

NT$33.00+NT$1.00 (+3.13%)today

−29.82%CAGR −7.56%

Select date range

FromTo

Feb 22, 2022Feb 22, 2022 → Aug 26, 2026· 4.5 yrsAug 26, 2026

Key Metrics

6875.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$53.38M

Net Income−NT$351.33M

Net Margin−658.1%

Operating Cash Flow−NT$319.30M

Capital ExpendituresNT$179.93M

Free Cash Flow−NT$499.23M

Return on Equity−25.7%

Return on Invested Capital−5.9%

Net CashNT$592.39M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6875.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6875.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6875.TWO and 80,000+ other tickers.

About Pharmosa Biopharm Inc.

Pharmosa Biopharm Inc., a biotechnology firm based in Taiwan, specializes in the development of pharmaceutical products. Its current pipeline includes two key candidates: L606 and L608. L606 is an investigational inhalation/device combination therapy designed to treat both pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease. Similarly, L608 is another inhalation-based therapy, paired with a device, aimed at addressing pulmonary vascular disease. The company, which was established in 2000, originally operated under the name Pharmosa Limited before…

CEO: Pei Kan
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 15
Website: www.pharmosa.com.tw

Peers

Peers Tab

4157.TWO

TaiGen Biopharmaceuticals Holdings Limited

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6875.TWO

What does Pharmosa Biopharm Inc. do?: Pharmosa Biopharm Inc. (6875.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6875.TWO's market cap?: Pharmosa Biopharm Inc. (6875.TWO) has a market capitalization of approximately $4.26 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 6875.TWO pay a dividend?: No — Pharmosa Biopharm Inc. (6875.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6875.TWO profitable?: Pharmosa Biopharm Inc. (6875.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.